Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma

@inproceedings{Dong2013HistoneDI,
  title={Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma},
  author={Li Dong and Shu Pei Cheng and Zhong A. Zheng and Li Wang and Y. C. Shen and Zhi Xiang Shen and Sai Chen and Wei-Li Zhao},
  booktitle={Journal of hematology & oncology},
  year={2013}
}
BACKGROUND Burkitt leukemia/lymphoma is a major subtype of aggressive B-cell lymphoma. Biological targeted therapies on this disease need to be further investigated and may help to improve the clinical outcome of the patients. METHODS This study examined the anti-tumor activity of the histone deacetylases (HDAC) inhibitor valproic acid (VPA) combined with the mammalian target of rapamycin (MTOR) inhibitor temsirolimus in Burkitt leukemia/lymphoma cell lines, as well as in primary tumor cells… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Emerging roles of Myc in stem cell biology and novel tumor therapies

Journal of experimental & clinical cancer research : CR • 2018
View 1 Excerpt

Burkitt lymphoma in adolescents and young adults: management challenges

Adolescent health, medicine and therapeutics • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Similar Papers

Loading similar papers…